Prof Constantine Tam
Clinical (Professor)
Department of Medicine
920 Scholarly works
7 Projects
HIGHLIGHTS
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Journal article
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
DOI: 10.1182/bloodadvances.20210056212022
Research grants (ARC, NHMRC, MRFF)
Understanding and Averting Blood Cancer Resistance to Therapy
2019
Research grants (ARC, NHMRC, MRFF)
The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
2017
Research Grant
Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
RECENT SCHOLARLY WORKS
2026
Journal article
First-line treatment for CLL in the era of targeted therapy
DOI: 10.1038/s41408-025-01434-22026
Journal article
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
DOI: 10.1111/bjh.706202026
Journal article
A Computerized Cognitive Test for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Pilot Study
DOI: 10.1016/j.jtct.2026.02.0592026
Journal article
Cognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy
DOI: 10.1016/j.jtct.2026.03.0302026
Journal article
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.
DOI: 10.1016/j.cmi.2026.06.0192026
Journal article
Sonrotoclax (BGB-11417) zanubrutinib (SZ) vs venetoclax acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2).
DOI: 10.1200/jco.2026.44.16_suppl.tps70992026
Journal article
Marginal Zone Lymphoma is associated with dysregulated T cell immunity which is not altered by ibrutinib-venetoclax treatment
DOI: 10.1016/j.bneo.2026.1002602026
Journal article
Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.
DOI: 10.1200/jco.2026.44.16_suppl.7043